Clinical effect of rosuvastatin combined with calcium dobesilate on stage Ⅲ-Ⅳ diabetic nephropathy

Guan Qingcong; Ke Shasha; Xu Fang; Wang Honggang

doi:10.3760/j.issn.1673-4777.2019.08.015

Abstract：Objective The observe the clinical effect of rosuvastatin combined with calcium dobesilate on stage Ⅲ-Ⅳ diabetic nephropathy.Methods A total of 140 patients with diabetic nephropathy (DN) admitted to Taizhou Municipal Hospital,Zhejiang Province from January 2016 to January 2018 were randomly divided into control group and observation group,with 70 cases in each group.The control group took rosuvastatin and the observation group took rosuvastatin plus calcium dobesilate on the basis of routine treatment.Clinical efficacy and insulin resistance of were analyzed after treatment.Results There were no significant differences of renal function,blood sugar and islet function indexes between groups before treatment (all P ＞ 0.05).After treatment,levels of serum uric acid and homeostatic model assessment-β cell function index significantly increased in both groups;the levels in observation group were significantly higher than those in control group [(388 ± 25) μmol/L vs (367 ± 25) μμmol/L,(44 ± 7) vs (39 ± 6)].Levels of serum creatinine,blood urea nitrogen,fasting blood glucose,postprandial 2 h blood sugar,glycosylated hemoglobin and homeostatic model assessment-insulin resistance significantly decreased in both groups;the levels in observation group were significantly lower than those in control group [(333 ± 42) μmol/L vs (391 ± 26) μmol/L,(17 ± 4) mmol/L vs (20 ±6)mmol/L,(6.4±1.1) mmol/L vs (7.3 ±1.1) mmol/L,(9.4 ± 1.8) mmol/L vs (10.0 ±2.5)mmol/L,(6.0±1.2)％ vs (6.7±1.3)％,(2.1 ±0.5) vs (2.5 ±0.9)](all P＜0.05).Conclusion Rosuvastatin combined with calcium dobesilate can effectively improve renal function,insulin resistance and islet β cell function in patients with DN.